List of Excipients in Branded Drug CICLOPIROX OLAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leading Pharma LLC	CICLOPIROX OLAMINE	ciclopirox olamine	69315-309	BENZYL ALCOHOL
Leading Pharma LLC	CICLOPIROX OLAMINE	ciclopirox olamine	69315-309	CETYL ALCOHOL
Leading Pharma LLC	CICLOPIROX OLAMINE	ciclopirox olamine	69315-309	COCAMIDE
Leading Pharma LLC	CICLOPIROX OLAMINE	ciclopirox olamine	69315-309	LACTIC ACID
Leading Pharma LLC	CICLOPIROX OLAMINE	ciclopirox olamine	69315-309	MINERAL OIL

Generic Drugs Containing CICLOPIROX OLAMINE

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	ciclopirox olamine	0713-0638	BENZYL ALCOHOL
Cosette Pharmaceuticals Inc	ciclopirox olamine	0713-0638	CETYL ALCOHOL
Cosette Pharmaceuticals Inc	ciclopirox olamine	0713-0638	LACTIC ACID
Cosette Pharmaceuticals Inc	ciclopirox olamine	0713-0638	MINERAL OIL
Cosette Pharmaceuticals Inc	ciclopirox olamine	0713-0638	MYRISTYL ALCOHOL

What are the Most Frequently-Used Excipients in CICLOPIROX OLAMINE?

# Of NDCs	Excipient
21	BENZYL ALCOHOL
21	CETYL ALCOHOL
4	COCO DIETHANOLAMIDE
21	LACTIC ACID
15	LIGHT MINERAL OIL

Excipient Strategy and Commercial Opportunities for Ciclopirox Olamine

Last updated: February 25, 2026

What is the role of excipients in formulations of Ciclopirox Olamine?

Excipients serve multiple functions in Ciclopirox Olamine formulations. They aid in drug stability, facilitate absorption, control release profiles, improve patient compliance, and enhance product manufacturability. Common excipients include penetration enhancers, stabilizers, preservatives, and viscosity modifiers.

How does excipient selection influence Ciclopirox Olamine product performance?

The choice of excipients impacts efficacy, shelf life, and tolerability. For topical formulations, solvents like ethanol or propylene glycol enhance skin penetration. In oral formulations, surfactants improve solubility. Stabilizing agents prevent degradation, extending shelf life. Compatibility with active ingredient and regulatory approval are crucial for excipient selection.

What are current manufacturing trends for Ciclopirox Olamine?

Nanoparticle dispersions are increasingly used to improve drug penetration. Liposomal carriers are explored to reduce irritation and increase local availability. Microemulsions offer improved stability and bioavailability. These technologies often incorporate specialized excipients such as surfactants, co-solvents, and stabilizers.

What commercial opportunities exist within the excipient market for Ciclopirox Olamine?

The rapid growth of topical antifungal markets, especially in dermatology, creates opportunities for excipient suppliers offering specialized penetration enhancers and stabilizers. The emerging interest in nanotechnology formulations opens avenues for companies targeting nanoparticle stabilizers and delivery systems. Patent-protected excipients can command premium pricing and serve as barriers for generics.

How do regulatory considerations shape excipient strategies?

Regulatory agencies require comprehensive data on excipient safety and compatibility. For topical products, excipients must meet dermatological safety standards, often classified under pharmacopeias or regulatory guidelines (e.g., FDA, EMA). Novel excipients demand rigorous testing, delaying time-to-market but potentially allowing differentiation through optimized formulations.

What are the key patent and licensing opportunities?

Patents on specific excipient combinations, novel delivery systems, or stabilized formulations present licensing prospects. Licensing agreements with excipient manufacturers enable access to proprietary technologies. Developing unique excipient systems may lead to exclusivity and higher margins.

What competitive landscape exists for excipient suppliers?

Major excipient suppliers such as BASF, Dow, and Evonik develop products tailored for topical antifungals. Niche firms focus on nanocarrier stabilizers or penetration enhancers. Partnerships with pharmaceutical companies foster innovation and access to regulatory pathways.

Summary of main excipient strategies

Strategy	Description	Potential Benefit	Challenges
Use of penetration enhancers	Incorporate agents like propylene glycol, urea	Improve skin permeability	Skin irritation risk
Stabilization formulations	Use antioxidants or chelating agents	Extend shelf life	Compatibility issues
Liposomal or nanoparticle systems	Employ lipid-based carriers	Increase bioavailability	Manufacturing complexity
Patented excipients	Utilize proprietary stabilizers	Market differentiation	Licensing costs

Conclusions

The excipient landscape for Ciclopirox Olamine offers multiple avenues for product optimization and commercialization. Market expansion hinges on innovative delivery systems, regulatory compliance, and strategic licensing. Suppliers with differentiated formulations and proven safety profiles can capitalize on growth trends in dermatology.

Key Takeaways

• Excipient choice directly influences drug efficacy, stability, and patient tolerability.
• Technologies such as nanoparticles and liposomes are increasingly relevant for topical formulations.
• Regulatory compliance remains a primary obstacle for novel excipients but offers market differentiation.
• The growing dermatology market enhances opportunities for excipient suppliers targeting antifungal products.
• Patents on delivery systems or excipient compositions protect market share and foster licensing deals.

FAQs

1. What excipients are most commonly used in Ciclopirox Olamine topical formulations?
2. How does nanoparticle technology improve Ciclopirox Olamine delivery?
3. Are there regulatory restrictions on excipients in antifungal products?
4. What factors influence the selection of penetration enhancers?
5. How can companies protect innovations in excipient formulations?

---

References

[1] US Food and Drug Administration. (2022). Guidance for Industry: Excipient List.
[2] European Medicines Agency. (2023). Committee for Medicinal Products for Human Use (CHMP) Guideline on Excipients.
[3] Smith, J., & Lee, K. (2021). Advances in Liposomal Delivery Systems for Topical Antifungals. Journal of Drug Delivery Science and Technology.
[4] Johnson, P., et al. (2020). Patent Landscape of Nanocarrier Systems in Dermatology. Pharmaceutical Patent Analyst.